Among the biggest conversations of The Democratic Debate was healthcare & that could have an impact on certain biotech penny stocks
June 26th of 2019 came with the first Democratic debate for the upcoming 2020 election. Of course, a hotly discussed topic was healthcare and the future of America’s system. Because of this, a lot of people’s eyes are on the healthcare sector and how healthcare penny stocks will react. Although the future of the industry is still uncertain, there are certain healthcare and biotech penny stocks seeing big moves.
With another debate scheduled for the 27th will these be the best healthcare penny stocks to buy? Or should you stick to the sideline for now? No matter your stance, here are some penny stocks to watch on Thursday:
Biotech Penny Stocks To Watch #1:
Atossa Genetics Inc. (ATOS)
Atossa Genetics Inc. (ATOS Stock Report) is another biotechnology company but their attention is solely on breast cancer and other breast diseases. One of their biggest treatments is called Endoxifen which is used to prevent recurrence of breast cancer. ATOS stock is currently gapping up by 25% and will hopefully look to keep increasing. This gap up came courtesy of strong news by Atossa.
The company announced strong preliminary analysis from their Phase 2 study for their Endoxifen. “We are thrilled that our proprietary topical Endoxifen significantly reduced breast density. We believe that no other drug, other than tamoxifen, has been clinically demonstrated to significantly reduce breast density,” expressed Steven C. Quay, Ph.D., M.D., CEO and President of Atossa.
Biotech Penny Stocks To Watch #2:
Aileron Therapeutics Inc. (ALRN)
Aileron Therapeutics Inc. (ALRN Stock Report) is a biopharmaceutical company focused on developing cell-permeating peptides to treat cancer. The company currently has 1 drug undergoing clinical trials for multiple treatment plans. Their leading drug is called ALRN-6924 and it mimics the p53 tumor suppressor protein to attack several forms of cancer.
Recently, this biotech penny stock announced big news involving their ALRN-6924 treatment. The FDA accepted the drug as a myelopreservation agent for those with p53-mutant cancer. As a result of this news, Aileron’s stock price made a strong premarket move. ALRN stock price also increased by over 25% in premarket all the way to $0.96.
Biotech Penny Stocks To Watch #3:
Kitov Pharma Ltd. (KTOV)
Kitov Pharma Ltd. (KTOV Stock Report) is a drug development company that does not have a specific disease they target. As of now, the company has developed 2 drugs, Consensi and NT-219. Consensi has already passed through all of its clinical trials and is being sold. Their NT-219 treatment just completed its IND-enabling studies which caused KTOV stock to shoot up 12% premarket.
“Our planned development of NT219 is based on strong preclinical evidence demonstrating that the combination of NT219 with the EGFR antibody cetuximab has potential clinical benefits for patients with recurrent or metastatic SCCHN whose cancer has not responded or has become resistant to early-line immuno-oncology or chemotherapy treatments. Pending a smooth regulatory review process, we look forward to initiating a Phase 1/2 trial with NT219 and cetuximab in the U.S. by the end of 2019,” explained Isaac Israel, CEO of Kitov.